➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
McKesson
Merck
Medtronic
McKinsey

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Insulin glargine - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for insulin glargine

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Institute of Neurosciences and Hospital, DhakaPhase 4
Shenzhen Second People's HospitalN/A
Ministry of Health, KuwaitPhase 4

See all insulin glargine clinical trials

Recent Litigation for insulin glargine

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08
Purdue Pharmaceutical v. Actavis Elizabeth LLC2015-05-13

See all insulin glargine litigation

Company Disclosures: US Patents for insulin glargine

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Get Started Free Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Get Started Free Medimpex Ets (LI) 2013-04-23 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Get Started Free Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 RX company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Get Started Free Medimpex Ets. (Balzers, LI) 2012-02-21 company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Get Started Free Medimpex Ets (LI) 2013-04-23 company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Get Started Free Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 company
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Get Started Free Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for insulin glargine

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin glargine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2000 Austria   Get Started Free PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 - EU/1/00/134/007 20000609
90042 Netherlands   Get Started Free PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
0885961/01 Switzerland   Get Started Free PRODUCT NAME: INSULIN GLULISIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57013 02.05.2005
00160 Netherlands   Get Started Free PRODUCT NAME: INSULINE DETEMIRUM; NAT. REGISTRATION NO/DATE: EU/1/04/278/001EU/1/04/278/002EU/1/04/278/003EU/1/04/278/005EU/1/04/278/004EU/1/04/278/006EU/1/04/278/007EU/1/04/278/008EU/1/04/278/009 2004010601; FIRST REGISTRATION: 563705637156372EU/1/04/278/001 T/M -/009 2003101110
05C/006 Belgium   Get Started Free PRODUCT NAME: INSULIN GLULISINE; AUTHORISATION NUMBER AND DATE: EU/1/04/285/001 20040928
C/GB00/022 United Kingdom   Get Started Free PRODUCT NAME: INSULIN GLARGINE (LANTUS) OPTIONALLY IN THE FORM OF ESTERS THEREOF OR PHYSIOLOGICALLY TOLERATED SALTS THEREOF.; REGISTERED: UK EU/1/00/134/001 20000609; UK EU/1/00/134/002 20000609; UK EU/1/00/134/003 20000609; UK EU/1/00/134/004 20000609; UK EU/1/00/134/005 20000609; UK EU/1/00/134/006 20000609; UK EU/1/00/134/007 20000609
2006901385693 Italy   Get Started Free PRODUCT NAME: SOSPENSIONE CONTENENTE INSULINA ASPART SOLUBILE E CRISTALLI DI INSULINA ASPART PROTAMINATA NEL RAPPORTO 70/30(NOVOMIX 70); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/142/017-018-019-020-021-022, 20051005
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Mallinckrodt
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.